After confirming the systemic release of secretory factors (IL-6 and G-CSF), their molecular signaling, alterations to the tumor immune landscape and determining the prognostic importance of the gene signature generated, we next investigated whether inhibiting these cytokines or MEK signaling would prevent cancer dormancy escape. The gene discussed is MAP2K7; the disease is cancer.